nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltitrexed—Methotrexate—esophageal cancer	0.413	1	CrCtD
Raltitrexed—TYMS—Capecitabine—esophageal cancer	0.12	0.444	CbGbCtD
Raltitrexed—FPGS—Methotrexate—esophageal cancer	0.111	0.411	CbGbCtD
Raltitrexed—Tetrahydrofolic acid—Methotrexate—esophageal cancer	0.0547	0.2	CrCrCtD
Raltitrexed—Leucovorin—Methotrexate—esophageal cancer	0.0547	0.2	CrCrCtD
Raltitrexed—Pemetrexed—Methotrexate—esophageal cancer	0.0547	0.2	CrCrCtD
Raltitrexed—Pralatrexate—Methotrexate—esophageal cancer	0.0547	0.2	CrCrCtD
Raltitrexed—Folic Acid—Methotrexate—esophageal cancer	0.0547	0.2	CrCrCtD
Raltitrexed—TYMS—Methotrexate—esophageal cancer	0.0392	0.145	CbGbCtD
Raltitrexed—FPGS—Fluoropyrimidine Activity—XRCC3—esophageal cancer	0.002	0.0929	CbGpPWpGaD
Raltitrexed—FPGS—Fluoropyrimidine Activity—TYMP—esophageal cancer	0.00168	0.0778	CbGpPWpGaD
Raltitrexed—FPGS—Defective AMN causes hereditary megaloblastic anemia 1—SLC52A3—esophageal cancer	0.00127	0.0591	CbGpPWpGaD
Raltitrexed—FPGS—Fluoropyrimidine Activity—CYP2A6—esophageal cancer	0.00116	0.0539	CbGpPWpGaD
Raltitrexed—Extravasation—Carboplatin—esophageal cancer	0.00105	0.072	CcSEcCtD
Raltitrexed—FPGS—bronchus—esophageal cancer	0.000971	0.159	CbGeAlD
Raltitrexed—FPGS—Fluoropyrimidine Activity—SMUG1—esophageal cancer	0.000947	0.0439	CbGpPWpGaD
Raltitrexed—FPGS—trachea—esophageal cancer	0.000872	0.143	CbGeAlD
Raltitrexed—TYMS—Pyrimidine metabolism—TYMP—esophageal cancer	0.000789	0.0366	CbGpPWpGaD
Raltitrexed—FPGS—digestive system—esophageal cancer	0.00075	0.123	CbGeAlD
Raltitrexed—TYMS—Fluoropyrimidine Activity—XRCC3—esophageal cancer	0.00073	0.0339	CbGpPWpGaD
Raltitrexed—FPGS—Defective AMN causes hereditary megaloblastic anemia 1—GSTO1—esophageal cancer	0.000698	0.0324	CbGpPWpGaD
Raltitrexed—TYMS—bronchus—esophageal cancer	0.000637	0.105	CbGeAlD
Raltitrexed—FPGS—lung—esophageal cancer	0.000626	0.103	CbGeAlD
Raltitrexed—TYMS—smooth muscle tissue—esophageal cancer	0.000623	0.102	CbGeAlD
Raltitrexed—TYMS—Fluoropyrimidine Activity—TYMP—esophageal cancer	0.000611	0.0284	CbGpPWpGaD
Raltitrexed—TYMS—digestive system—esophageal cancer	0.000492	0.0808	CbGeAlD
Raltitrexed—Sinus tachycardia—Capecitabine—esophageal cancer	0.000491	0.0337	CcSEcCtD
Raltitrexed—Febrile neutropenia—Cisplatin—esophageal cancer	0.000446	0.0306	CcSEcCtD
Raltitrexed—FPGS—lymph node—esophageal cancer	0.000428	0.0703	CbGeAlD
Raltitrexed—TYMS—Fluoropyrimidine Activity—CYP2A6—esophageal cancer	0.000424	0.0197	CbGpPWpGaD
Raltitrexed—Leucovorin—ABCC2—esophageal cancer	0.000416	0.445	CrCbGaD
Raltitrexed—TYMS—lung—esophageal cancer	0.000411	0.0675	CbGeAlD
Raltitrexed—TYMS—Fluoropyrimidine Activity—SMUG1—esophageal cancer	0.000345	0.016	CbGpPWpGaD
Raltitrexed—Necrosis—Cisplatin—esophageal cancer	0.000342	0.0235	CcSEcCtD
Raltitrexed—Febrile neutropenia—Capecitabine—esophageal cancer	0.000329	0.0226	CcSEcCtD
Raltitrexed—Infection—Carboplatin—esophageal cancer	0.000324	0.0223	CcSEcCtD
Raltitrexed—Extravasation—Cisplatin—esophageal cancer	0.000307	0.0211	CcSEcCtD
Raltitrexed—TYMS—Nucleotide metabolism—TYMP—esophageal cancer	0.000307	0.0143	CbGpPWpGaD
Raltitrexed—Supraventricular tachycardia—Capecitabine—esophageal cancer	0.000302	0.0207	CcSEcCtD
Raltitrexed—Cellulitis—Cisplatin—esophageal cancer	0.000295	0.0203	CcSEcCtD
Raltitrexed—TYMS—lymph node—esophageal cancer	0.000281	0.0461	CbGeAlD
Raltitrexed—TYMS—E2F transcription factor network—XRCC1—esophageal cancer	0.000281	0.013	CbGpPWpGaD
Raltitrexed—Pain—Carboplatin—esophageal cancer	0.000279	0.0192	CcSEcCtD
Raltitrexed—Tetrahydrofolic acid—ABCC2—esophageal cancer	0.000268	0.287	CrCbGaD
Raltitrexed—Body temperature increased—Carboplatin—esophageal cancer	0.000258	0.0177	CcSEcCtD
Raltitrexed—Skin exfoliation—Cisplatin—esophageal cancer	0.000256	0.0176	CcSEcCtD
Raltitrexed—FPGS—Fluoropyrimidine Activity—TP53—esophageal cancer	0.000251	0.0117	CbGpPWpGaD
Raltitrexed—Febrile neutropenia—Methotrexate—esophageal cancer	0.000245	0.0168	CcSEcCtD
Raltitrexed—Cellulitis—Capecitabine—esophageal cancer	0.000217	0.0149	CcSEcCtD
Raltitrexed—Cardiac failure congestive—Cisplatin—esophageal cancer	0.000215	0.0147	CcSEcCtD
Raltitrexed—TYMS—Circadian rythm related genes—CRTC1—esophageal cancer	0.000202	0.00938	CbGpPWpGaD
Raltitrexed—FPGS—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—esophageal cancer	0.000194	0.00902	CbGpPWpGaD
Raltitrexed—Influenza like illness—Capecitabine—esophageal cancer	0.000192	0.0132	CcSEcCtD
Raltitrexed—Skin exfoliation—Capecitabine—esophageal cancer	0.000189	0.013	CcSEcCtD
Raltitrexed—Necrosis—Methotrexate—esophageal cancer	0.000188	0.0129	CcSEcCtD
Raltitrexed—TYMS—E2F mediated regulation of DNA replication—RB1—esophageal cancer	0.000187	0.00869	CbGpPWpGaD
Raltitrexed—Methotrexate—ABCC2—esophageal cancer	0.000184	0.196	CrCbGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.000183	0.0085	CbGpPWpGaD
Raltitrexed—Dehydration—Cisplatin—esophageal cancer	0.000181	0.0124	CcSEcCtD
Raltitrexed—Mouth ulceration—Capecitabine—esophageal cancer	0.000179	0.0123	CcSEcCtD
Raltitrexed—Sepsis—Capecitabine—esophageal cancer	0.000172	0.0118	CcSEcCtD
Raltitrexed—Extravasation—Methotrexate—esophageal cancer	0.000169	0.0116	CcSEcCtD
Raltitrexed—TYMS—Retinoblastoma (RB) in Cancer—HMGB1—esophageal cancer	0.000162	0.0075	CbGpPWpGaD
Raltitrexed—Hepatic failure—Capecitabine—esophageal cancer	0.00016	0.011	CcSEcCtD
Raltitrexed—TYMS—G1/S Transition—PSME2—esophageal cancer	0.000152	0.00706	CbGpPWpGaD
Raltitrexed—TYMS—G1/S Transition—PSME1—esophageal cancer	0.000152	0.00706	CbGpPWpGaD
Raltitrexed—Atrial fibrillation—Capecitabine—esophageal cancer	0.000151	0.0104	CcSEcCtD
Raltitrexed—FPGS—Disease—SLC52A3—esophageal cancer	0.000151	0.007	CbGpPWpGaD
Raltitrexed—Renal impairment—Capecitabine—esophageal cancer	0.000151	0.0104	CcSEcCtD
Raltitrexed—Renal failure—Cisplatin—esophageal cancer	0.000148	0.0101	CcSEcCtD
Raltitrexed—Stomatitis—Cisplatin—esophageal cancer	0.000146	0.01	CcSEcCtD
Raltitrexed—Conjunctivitis—Cisplatin—esophageal cancer	0.000146	0.01	CcSEcCtD
Raltitrexed—FPGS—Disease—KMT2D—esophageal cancer	0.000144	0.00668	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.000142	0.0066	CbGpPWpGaD
Raltitrexed—Skin exfoliation—Methotrexate—esophageal cancer	0.000141	0.00965	CcSEcCtD
Raltitrexed—TYMS—Retinoblastoma (RB) in Cancer—ABL1—esophageal cancer	0.000134	0.00621	CbGpPWpGaD
Raltitrexed—Dehydration—Capecitabine—esophageal cancer	0.000133	0.00917	CcSEcCtD
Raltitrexed—Mouth ulceration—Methotrexate—esophageal cancer	0.000133	0.00914	CcSEcCtD
Raltitrexed—TYMS—Mitotic G1-G1/S phases—PSME1—esophageal cancer	0.000128	0.00595	CbGpPWpGaD
Raltitrexed—TYMS—Mitotic G1-G1/S phases—PSME2—esophageal cancer	0.000128	0.00595	CbGpPWpGaD
Raltitrexed—Sepsis—Methotrexate—esophageal cancer	0.000128	0.00877	CcSEcCtD
Raltitrexed—TYMS—Cell Cycle, Mitotic—AJUBA—esophageal cancer	0.000126	0.00587	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—BLVRB—esophageal cancer	0.000126	0.00586	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—SLC52A3—esophageal cancer	0.000126	0.00586	CbGpPWpGaD
Raltitrexed—Arrhythmia—Cisplatin—esophageal cancer	0.00012	0.00827	CcSEcCtD
Raltitrexed—Alopecia—Cisplatin—esophageal cancer	0.000119	0.00818	CcSEcCtD
Raltitrexed—Hepatic failure—Methotrexate—esophageal cancer	0.000119	0.00817	CcSEcCtD
Raltitrexed—Neutropenia—Capecitabine—esophageal cancer	0.000116	0.00797	CcSEcCtD
Raltitrexed—TYMS—Cell Cycle—AJUBA—esophageal cancer	0.000113	0.00525	CbGpPWpGaD
Raltitrexed—Weight decreased—Capecitabine—esophageal cancer	0.000112	0.00771	CcSEcCtD
Raltitrexed—FPGS—Disease—FKBP1A—esophageal cancer	0.000112	0.00518	CbGpPWpGaD
Raltitrexed—FPGS—Disease—DOCK2—esophageal cancer	0.000109	0.00506	CbGpPWpGaD
Raltitrexed—FPGS—Disease—WIF1—esophageal cancer	0.000109	0.00506	CbGpPWpGaD
Raltitrexed—Ill-defined disorder—Cisplatin—esophageal cancer	0.000109	0.00747	CcSEcCtD
Raltitrexed—Renal failure—Capecitabine—esophageal cancer	0.000109	0.00747	CcSEcCtD
Raltitrexed—Anaemia—Cisplatin—esophageal cancer	0.000108	0.00744	CcSEcCtD
Raltitrexed—Stomatitis—Capecitabine—esophageal cancer	0.000108	0.00741	CcSEcCtD
Raltitrexed—Conjunctivitis—Capecitabine—esophageal cancer	0.000108	0.00738	CcSEcCtD
Raltitrexed—FPGS—Metabolism—CA1—esophageal cancer	0.000107	0.00499	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—SLC10A2—esophageal cancer	0.000107	0.00499	CbGpPWpGaD
Raltitrexed—Malaise—Cisplatin—esophageal cancer	0.000106	0.00726	CcSEcCtD
Raltitrexed—Leukopenia—Cisplatin—esophageal cancer	0.000105	0.00721	CcSEcCtD
Raltitrexed—TYMS—Cell Cycle—MLH3—esophageal cancer	0.000102	0.00475	CbGpPWpGaD
Raltitrexed—FPGS—Disease—CSNK1A1—esophageal cancer	0.000101	0.00467	CbGpPWpGaD
Raltitrexed—TYMS—E2F transcription factor network—CREBBP—esophageal cancer	9.96e-05	0.00462	CbGpPWpGaD
Raltitrexed—TYMS—E2F transcription factor network—RB1—esophageal cancer	9.92e-05	0.0046	CbGpPWpGaD
Raltitrexed—Discomfort—Cisplatin—esophageal cancer	9.86e-05	0.00677	CcSEcCtD
Raltitrexed—FPGS—Metabolism—CA2—esophageal cancer	9.83e-05	0.00456	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	9.67e-05	0.00449	CbGpPWpGaD
Raltitrexed—Oedema—Cisplatin—esophageal cancer	9.57e-05	0.00657	CcSEcCtD
Raltitrexed—Infection—Cisplatin—esophageal cancer	9.51e-05	0.00653	CcSEcCtD
Raltitrexed—Thrombocytopenia—Cisplatin—esophageal cancer	9.37e-05	0.00644	CcSEcCtD
Raltitrexed—Hyperhidrosis—Cisplatin—esophageal cancer	9.25e-05	0.00635	CcSEcCtD
Raltitrexed—TYMS—Fluoropyrimidine Activity—TP53—esophageal cancer	9.16e-05	0.00425	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—PLCE1—esophageal cancer	9.14e-05	0.00424	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—ADH7—esophageal cancer	9.14e-05	0.00424	CbGpPWpGaD
Raltitrexed—Anorexia—Cisplatin—esophageal cancer	9.12e-05	0.00627	CcSEcCtD
Raltitrexed—Arrhythmia—Capecitabine—esophageal cancer	8.87e-05	0.00609	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	8.84e-05	0.0041	CbGpPWpGaD
Raltitrexed—TYMS—Circadian rythm related genes—GHRL—esophageal cancer	8.8e-05	0.00408	CbGpPWpGaD
Raltitrexed—Alopecia—Capecitabine—esophageal cancer	8.78e-05	0.00603	CcSEcCtD
Raltitrexed—TYMS—E2F transcription factor network—CDKN2A—esophageal cancer	8.72e-05	0.00405	CbGpPWpGaD
Raltitrexed—Musculoskeletal discomfort—Cisplatin—esophageal cancer	8.72e-05	0.00599	CcSEcCtD
Raltitrexed—Neutropenia—Methotrexate—esophageal cancer	8.64e-05	0.00593	CcSEcCtD
Raltitrexed—TYMS—Retinoblastoma (RB) in Cancer—RB1—esophageal cancer	8.62e-05	0.004	CbGpPWpGaD
Raltitrexed—Dysgeusia—Capecitabine—esophageal cancer	8.47e-05	0.00581	CcSEcCtD
Raltitrexed—FPGS—Disease—ELMO1—esophageal cancer	8.46e-05	0.00393	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	8.41e-05	0.0039	CbGpPWpGaD
Raltitrexed—Decreased appetite—Cisplatin—esophageal cancer	8.32e-05	0.00571	CcSEcCtD
Raltitrexed—FPGS—Disease—TPI1—esophageal cancer	8.27e-05	0.00384	CbGpPWpGaD
Raltitrexed—FPGS—Disease—GSTO1—esophageal cancer	8.27e-05	0.00384	CbGpPWpGaD
Raltitrexed—Pain—Cisplatin—esophageal cancer	8.18e-05	0.00562	CcSEcCtD
Raltitrexed—Renal failure—Methotrexate—esophageal cancer	8.09e-05	0.00556	CcSEcCtD
Raltitrexed—Stomatitis—Methotrexate—esophageal cancer	8.03e-05	0.00551	CcSEcCtD
Raltitrexed—Ill-defined disorder—Capecitabine—esophageal cancer	8.02e-05	0.00551	CcSEcCtD
Raltitrexed—FPGS—Metabolism—ADH1B—esophageal cancer	8.01e-05	0.00372	CbGpPWpGaD
Raltitrexed—Conjunctivitis—Methotrexate—esophageal cancer	8e-05	0.0055	CcSEcCtD
Raltitrexed—Anaemia—Capecitabine—esophageal cancer	7.99e-05	0.00549	CcSEcCtD
Raltitrexed—FPGS—Disease—ALDOB—esophageal cancer	7.93e-05	0.00368	CbGpPWpGaD
Raltitrexed—Sweating—Methotrexate—esophageal cancer	7.89e-05	0.00542	CcSEcCtD
Raltitrexed—Feeling abnormal—Cisplatin—esophageal cancer	7.89e-05	0.00542	CcSEcCtD
Raltitrexed—Malaise—Capecitabine—esophageal cancer	7.8e-05	0.00535	CcSEcCtD
Raltitrexed—Leukopenia—Capecitabine—esophageal cancer	7.74e-05	0.00531	CcSEcCtD
Raltitrexed—FPGS—Metabolism—TYMP—esophageal cancer	7.66e-05	0.00355	CbGpPWpGaD
Raltitrexed—FPGS—Disease—HIST1H2BM—esophageal cancer	7.63e-05	0.00354	CbGpPWpGaD
Raltitrexed—FPGS—Disease—GAPDH—esophageal cancer	7.63e-05	0.00354	CbGpPWpGaD
Raltitrexed—Body temperature increased—Cisplatin—esophageal cancer	7.57e-05	0.0052	CcSEcCtD
Raltitrexed—Cough—Capecitabine—esophageal cancer	7.54e-05	0.00518	CcSEcCtD
Raltitrexed—FPGS—Metabolism—CYP26A1—esophageal cancer	7.45e-05	0.00346	CbGpPWpGaD
Raltitrexed—Arthralgia—Capecitabine—esophageal cancer	7.36e-05	0.00505	CcSEcCtD
Raltitrexed—Discomfort—Capecitabine—esophageal cancer	7.27e-05	0.00499	CcSEcCtD
Raltitrexed—FPGS—Metabolism—ALOX15—esophageal cancer	7.26e-05	0.00337	CbGpPWpGaD
Raltitrexed—TYMS—G1/S Transition—RB1—esophageal cancer	7.2e-05	0.00334	CbGpPWpGaD
Raltitrexed—TYMS—E2F transcription factor network—CDKN1A—esophageal cancer	7.13e-05	0.00331	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	7.13e-05	0.00331	CbGpPWpGaD
Raltitrexed—Oedema—Capecitabine—esophageal cancer	7.06e-05	0.00485	CcSEcCtD
Raltitrexed—Infection—Capecitabine—esophageal cancer	7.01e-05	0.00481	CcSEcCtD
Raltitrexed—FPGS—Metabolism—TPI1—esophageal cancer	6.92e-05	0.00321	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—GSTO1—esophageal cancer	6.92e-05	0.00321	CbGpPWpGaD
Raltitrexed—Thrombocytopenia—Capecitabine—esophageal cancer	6.91e-05	0.00474	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	6.9e-05	0.0032	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	6.9e-05	0.0032	CbGpPWpGaD
Raltitrexed—Asthenia—Cisplatin—esophageal cancer	6.87e-05	0.00472	CcSEcCtD
Raltitrexed—Hyperhidrosis—Capecitabine—esophageal cancer	6.82e-05	0.00468	CcSEcCtD
Raltitrexed—TYMS—E2F transcription factor network—EP300—esophageal cancer	6.78e-05	0.00315	CbGpPWpGaD
Raltitrexed—Methotrexate—ABCB1—esophageal cancer	6.75e-05	0.0722	CrCbGaD
Raltitrexed—FPGS—Disease—XIAP—esophageal cancer	6.74e-05	0.00313	CbGpPWpGaD
Raltitrexed—Anorexia—Capecitabine—esophageal cancer	6.72e-05	0.00462	CcSEcCtD
Raltitrexed—FPGS—Metabolism—ALDOB—esophageal cancer	6.64e-05	0.00308	CbGpPWpGaD
Raltitrexed—Diarrhoea—Cisplatin—esophageal cancer	6.55e-05	0.0045	CcSEcCtD
Raltitrexed—Alopecia—Methotrexate—esophageal cancer	6.53e-05	0.00449	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	6.53e-05	0.00303	CbGpPWpGaD
Raltitrexed—Musculoskeletal discomfort—Capecitabine—esophageal cancer	6.43e-05	0.00441	CcSEcCtD
Raltitrexed—TYMS—Retinoblastoma (RB) in Cancer—CCND1—esophageal cancer	6.4e-05	0.00297	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—GAPDH—esophageal cancer	6.39e-05	0.00297	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—CRABP1—esophageal cancer	6.33e-05	0.00294	CbGpPWpGaD
Raltitrexed—Dysgeusia—Methotrexate—esophageal cancer	6.3e-05	0.00433	CcSEcCtD
Raltitrexed—FPGS—Disease—B2M—esophageal cancer	6.27e-05	0.00291	CbGpPWpGaD
Raltitrexed—Dyspepsia—Capecitabine—esophageal cancer	6.21e-05	0.00427	CcSEcCtD
Raltitrexed—TYMS—Retinoblastoma (RB) in Cancer—CDKN1A—esophageal cancer	6.2e-05	0.00288	CbGpPWpGaD
Raltitrexed—Decreased appetite—Capecitabine—esophageal cancer	6.13e-05	0.00421	CcSEcCtD
Raltitrexed—Vomiting—Cisplatin—esophageal cancer	6.09e-05	0.00418	CcSEcCtD
Raltitrexed—TYMS—Mitotic G1-G1/S phases—RB1—esophageal cancer	6.07e-05	0.00282	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle, Mitotic—HIST1H2BM—esophageal cancer	6.06e-05	0.00281	CbGpPWpGaD
Raltitrexed—Rash—Cisplatin—esophageal cancer	6.03e-05	0.00414	CcSEcCtD
Raltitrexed—Constipation—Capecitabine—esophageal cancer	6.03e-05	0.00414	CcSEcCtD
Raltitrexed—Pain—Capecitabine—esophageal cancer	6.03e-05	0.00414	CcSEcCtD
Raltitrexed—Dermatitis—Cisplatin—esophageal cancer	6.03e-05	0.00414	CcSEcCtD
Raltitrexed—FPGS—Metabolism—GNG7—esophageal cancer	6.02e-05	0.00279	CbGpPWpGaD
Raltitrexed—FPGS—Disease—ENO1—esophageal cancer	6.01e-05	0.00279	CbGpPWpGaD
Raltitrexed—Ill-defined disorder—Methotrexate—esophageal cancer	5.97e-05	0.0041	CcSEcCtD
Raltitrexed—Anaemia—Methotrexate—esophageal cancer	5.95e-05	0.00408	CcSEcCtD
Raltitrexed—FPGS—Disease—PSME1—esophageal cancer	5.92e-05	0.00275	CbGpPWpGaD
Raltitrexed—FPGS—Disease—PSME2—esophageal cancer	5.92e-05	0.00275	CbGpPWpGaD
Raltitrexed—TYMS—E2F transcription factor network—MYC—esophageal cancer	5.91e-05	0.00274	CbGpPWpGaD
Raltitrexed—Feeling abnormal—Capecitabine—esophageal cancer	5.81e-05	0.00399	CcSEcCtD
Raltitrexed—Malaise—Methotrexate—esophageal cancer	5.8e-05	0.00399	CcSEcCtD
Raltitrexed—Gastrointestinal pain—Capecitabine—esophageal cancer	5.77e-05	0.00396	CcSEcCtD
Raltitrexed—Leukopenia—Methotrexate—esophageal cancer	5.76e-05	0.00396	CcSEcCtD
Raltitrexed—Nausea—Cisplatin—esophageal cancer	5.68e-05	0.0039	CcSEcCtD
Raltitrexed—FPGS—Disease—CALR—esophageal cancer	5.68e-05	0.00264	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—ALDH2—esophageal cancer	5.64e-05	0.00262	CbGpPWpGaD
Raltitrexed—Cough—Methotrexate—esophageal cancer	5.62e-05	0.00386	CcSEcCtD
Raltitrexed—Abdominal pain—Capecitabine—esophageal cancer	5.58e-05	0.00383	CcSEcCtD
Raltitrexed—Body temperature increased—Capecitabine—esophageal cancer	5.58e-05	0.00383	CcSEcCtD
Raltitrexed—FPGS—Disease—FBXW7—esophageal cancer	5.49e-05	0.00255	CbGpPWpGaD
Raltitrexed—Arthralgia—Methotrexate—esophageal cancer	5.48e-05	0.00376	CcSEcCtD
Raltitrexed—TYMS—Cell Cycle—HIST1H2BM—esophageal cancer	5.42e-05	0.00252	CbGpPWpGaD
Raltitrexed—Discomfort—Methotrexate—esophageal cancer	5.41e-05	0.00372	CcSEcCtD
Raltitrexed—FPGS—Metabolism—GSTT1—esophageal cancer	5.37e-05	0.00249	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle, Mitotic—MAD2L1—esophageal cancer	5.36e-05	0.00249	CbGpPWpGaD
Raltitrexed—TYMS—Mitotic G1-G1/S phases—CDKN2A—esophageal cancer	5.33e-05	0.00248	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—CYP2A6—esophageal cancer	5.31e-05	0.00246	CbGpPWpGaD
Raltitrexed—Infection—Methotrexate—esophageal cancer	5.22e-05	0.00358	CcSEcCtD
Raltitrexed—TYMS—G1/S Transition—CDKN1A—esophageal cancer	5.17e-05	0.0024	CbGpPWpGaD
Raltitrexed—Thrombocytopenia—Methotrexate—esophageal cancer	5.14e-05	0.00353	CcSEcCtD
Raltitrexed—TYMS—Retinoblastoma (RB) in Cancer—MYC—esophageal cancer	5.14e-05	0.00238	CbGpPWpGaD
Raltitrexed—Hyperhidrosis—Methotrexate—esophageal cancer	5.08e-05	0.00349	CcSEcCtD
Raltitrexed—Asthenia—Capecitabine—esophageal cancer	5.06e-05	0.00348	CcSEcCtD
Raltitrexed—FPGS—Metabolism—PTGS1—esophageal cancer	5.03e-05	0.00233	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—ENO1—esophageal cancer	5.03e-05	0.00233	CbGpPWpGaD
Raltitrexed—Anorexia—Methotrexate—esophageal cancer	5.01e-05	0.00344	CcSEcCtD
Raltitrexed—Pruritus—Capecitabine—esophageal cancer	4.99e-05	0.00343	CcSEcCtD
Raltitrexed—FPGS—Metabolism—PSME1—esophageal cancer	4.96e-05	0.0023	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—PSME2—esophageal cancer	4.96e-05	0.0023	CbGpPWpGaD
Raltitrexed—TYMS—Circadian rythm related genes—NOS2—esophageal cancer	4.93e-05	0.00229	CbGpPWpGaD
Raltitrexed—Diarrhoea—Capecitabine—esophageal cancer	4.83e-05	0.00332	CcSEcCtD
Raltitrexed—TYMS—Cell Cycle—MAD2L1—esophageal cancer	4.79e-05	0.00222	CbGpPWpGaD
Raltitrexed—Musculoskeletal discomfort—Methotrexate—esophageal cancer	4.78e-05	0.00329	CcSEcCtD
Raltitrexed—TYMS—Cell Cycle, Mitotic—PSME2—esophageal cancer	4.7e-05	0.00218	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle, Mitotic—PSME1—esophageal cancer	4.7e-05	0.00218	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	4.64e-05	0.00215	CbGpPWpGaD
Raltitrexed—Dyspepsia—Methotrexate—esophageal cancer	4.62e-05	0.00318	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	4.61e-05	0.00214	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—BLVRB—esophageal cancer	4.61e-05	0.00214	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—SLC52A3—esophageal cancer	4.61e-05	0.00214	CbGpPWpGaD
Raltitrexed—Decreased appetite—Methotrexate—esophageal cancer	4.57e-05	0.00314	CcSEcCtD
Raltitrexed—TYMS—Mitotic G1-G1/S phases—CCND1—esophageal cancer	4.51e-05	0.00209	CbGpPWpGaD
Raltitrexed—Pain—Methotrexate—esophageal cancer	4.49e-05	0.00308	CcSEcCtD
Raltitrexed—Vomiting—Capecitabine—esophageal cancer	4.49e-05	0.00308	CcSEcCtD
Raltitrexed—Rash—Capecitabine—esophageal cancer	4.45e-05	0.00306	CcSEcCtD
Raltitrexed—Dermatitis—Capecitabine—esophageal cancer	4.44e-05	0.00305	CcSEcCtD
Raltitrexed—FPGS—Disease—TGFBR2—esophageal cancer	4.44e-05	0.00206	CbGpPWpGaD
Raltitrexed—Headache—Capecitabine—esophageal cancer	4.42e-05	0.00304	CcSEcCtD
Raltitrexed—TYMS—Mitotic G1-G1/S phases—CDKN1A—esophageal cancer	4.36e-05	0.00202	CbGpPWpGaD
Raltitrexed—Feeling abnormal—Methotrexate—esophageal cancer	4.33e-05	0.00297	CcSEcCtD
Raltitrexed—Gastrointestinal pain—Methotrexate—esophageal cancer	4.29e-05	0.00295	CcSEcCtD
Raltitrexed—TYMS—G1/S Transition—MYC—esophageal cancer	4.29e-05	0.00199	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle, Mitotic—BUB1B—esophageal cancer	4.28e-05	0.00199	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—CYP1B1—esophageal cancer	4.28e-05	0.00198	CbGpPWpGaD
Raltitrexed—TYMS—Retinoblastoma (RB) in Cancer—TP53—esophageal cancer	4.22e-05	0.00196	CbGpPWpGaD
Raltitrexed—FPGS—Disease—SMAD4—esophageal cancer	4.21e-05	0.00195	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—PSME2—esophageal cancer	4.21e-05	0.00195	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—PSME1—esophageal cancer	4.21e-05	0.00195	CbGpPWpGaD
Raltitrexed—Nausea—Capecitabine—esophageal cancer	4.19e-05	0.00288	CcSEcCtD
Raltitrexed—Body temperature increased—Methotrexate—esophageal cancer	4.15e-05	0.00285	CcSEcCtD
Raltitrexed—Abdominal pain—Methotrexate—esophageal cancer	4.15e-05	0.00285	CcSEcCtD
Raltitrexed—FPGS—Metabolism—CYP19A1—esophageal cancer	4.02e-05	0.00187	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	3.98e-05	0.00185	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—CA1—esophageal cancer	3.92e-05	0.00182	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—SLC10A2—esophageal cancer	3.92e-05	0.00182	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	3.86e-05	0.00179	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—BUB1B—esophageal cancer	3.83e-05	0.00178	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	3.78e-05	0.00175	CbGpPWpGaD
Raltitrexed—Asthenia—Methotrexate—esophageal cancer	3.77e-05	0.00259	CcSEcCtD
Raltitrexed—Pruritus—Methotrexate—esophageal cancer	3.72e-05	0.00255	CcSEcCtD
Raltitrexed—FPGS—Metabolism—HMOX1—esophageal cancer	3.67e-05	0.0017	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—CHEK2—esophageal cancer	3.64e-05	0.00169	CbGpPWpGaD
Raltitrexed—TYMS—Mitotic G1-G1/S phases—MYC—esophageal cancer	3.61e-05	0.00168	CbGpPWpGaD
Raltitrexed—Diarrhoea—Methotrexate—esophageal cancer	3.59e-05	0.00247	CcSEcCtD
Raltitrexed—TYMS—Metabolism—CA2—esophageal cancer	3.58e-05	0.00166	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—ABCB1—esophageal cancer	3.52e-05	0.00163	CbGpPWpGaD
Raltitrexed—FPGS—Disease—HIF1A—esophageal cancer	3.44e-05	0.0016	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	3.41e-05	0.00158	CbGpPWpGaD
Raltitrexed—Vomiting—Methotrexate—esophageal cancer	3.34e-05	0.00229	CcSEcCtD
Raltitrexed—TYMS—Metabolism—ADH7—esophageal cancer	3.33e-05	0.00155	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—PLCE1—esophageal cancer	3.33e-05	0.00155	CbGpPWpGaD
Raltitrexed—Rash—Methotrexate—esophageal cancer	3.31e-05	0.00227	CcSEcCtD
Raltitrexed—Dermatitis—Methotrexate—esophageal cancer	3.31e-05	0.00227	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	3.3e-05	0.00153	CbGpPWpGaD
Raltitrexed—Headache—Methotrexate—esophageal cancer	3.29e-05	0.00226	CcSEcCtD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	3.14e-05	0.00146	CbGpPWpGaD
Raltitrexed—FPGS—Disease—NOS2—esophageal cancer	3.13e-05	0.00145	CbGpPWpGaD
Raltitrexed—Nausea—Methotrexate—esophageal cancer	3.12e-05	0.00214	CcSEcCtD
Raltitrexed—FPGS—Disease—NOTCH1—esophageal cancer	3.1e-05	0.00144	CbGpPWpGaD
Raltitrexed—TYMS—Circadian rythm related genes—EP300—esophageal cancer	3.02e-05	0.0014	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—ADH1B—esophageal cancer	2.92e-05	0.00135	CbGpPWpGaD
Raltitrexed—FPGS—Disease—CREBBP—esophageal cancer	2.81e-05	0.0013	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—TYMP—esophageal cancer	2.79e-05	0.00129	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	2.74e-05	0.00127	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—CYP26A1—esophageal cancer	2.71e-05	0.00126	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	2.68e-05	0.00124	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—ALOX15—esophageal cancer	2.65e-05	0.00123	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—TPI1—esophageal cancer	2.52e-05	0.00117	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—GSTO1—esophageal cancer	2.52e-05	0.00117	CbGpPWpGaD
Raltitrexed—FPGS—Disease—NOS3—esophageal cancer	2.52e-05	0.00117	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—ALDOB—esophageal cancer	2.42e-05	0.00112	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—CREBBP—esophageal cancer	2.35e-05	0.00109	CbGpPWpGaD
Raltitrexed—FPGS—Disease—ERBB2—esophageal cancer	2.35e-05	0.00109	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—GAPDH—esophageal cancer	2.33e-05	0.00108	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	2.32e-05	0.00108	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—CRABP1—esophageal cancer	2.31e-05	0.00107	CbGpPWpGaD
Raltitrexed—FPGS—Disease—PTGS2—esophageal cancer	2.3e-05	0.00107	CbGpPWpGaD
Raltitrexed—TYMS—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.25e-05	0.00104	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle, Mitotic—RB1—esophageal cancer	2.23e-05	0.00103	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—GNG7—esophageal cancer	2.2e-05	0.00102	CbGpPWpGaD
Raltitrexed—TYMS—Circadian rythm related genes—TP53—esophageal cancer	2.16e-05	0.001	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—NOS3—esophageal cancer	2.11e-05	0.000978	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—ALDH2—esophageal cancer	2.06e-05	0.000955	CbGpPWpGaD
Raltitrexed—FPGS—Disease—CDKN1A—esophageal cancer	2.01e-05	0.000934	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—RB1—esophageal cancer	1.99e-05	0.000923	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—GSTT1—esophageal cancer	1.96e-05	0.000908	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle, Mitotic—CDKN2A—esophageal cancer	1.96e-05	0.000908	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—CYP2A6—esophageal cancer	1.93e-05	0.000898	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—PTGS2—esophageal cancer	1.93e-05	0.000895	CbGpPWpGaD
Raltitrexed—FPGS—Disease—EP300—esophageal cancer	1.91e-05	0.000888	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—PTGS1—esophageal cancer	1.83e-05	0.000851	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—ENO1—esophageal cancer	1.83e-05	0.000851	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—PSME2—esophageal cancer	1.81e-05	0.000838	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—PSME1—esophageal cancer	1.81e-05	0.000838	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—CDKN2A—esophageal cancer	1.75e-05	0.000812	CbGpPWpGaD
Raltitrexed—FPGS—Disease—MYC—esophageal cancer	1.67e-05	0.000774	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle, Mitotic—CCND1—esophageal cancer	1.65e-05	0.000767	CbGpPWpGaD
Raltitrexed—FPGS—Disease—EGFR—esophageal cancer	1.63e-05	0.000757	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—EP300—esophageal cancer	1.6e-05	0.000744	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle, Mitotic—CDKN1A—esophageal cancer	1.6e-05	0.000742	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—CYP1B1—esophageal cancer	1.56e-05	0.000723	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle, Mitotic—EP300—esophageal cancer	1.52e-05	0.000706	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—CCND1—esophageal cancer	1.48e-05	0.000686	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—CYP19A1—esophageal cancer	1.47e-05	0.00068	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—CDKN1A—esophageal cancer	1.43e-05	0.000663	CbGpPWpGaD
Raltitrexed—FPGS—Disease—PIK3CA—esophageal cancer	1.42e-05	0.000657	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—EP300—esophageal cancer	1.36e-05	0.000631	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—HMOX1—esophageal cancer	1.34e-05	0.000621	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle, Mitotic—MYC—esophageal cancer	1.33e-05	0.000615	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—ABCB1—esophageal cancer	1.28e-05	0.000596	CbGpPWpGaD
Raltitrexed—FPGS—Metabolism—PIK3CA—esophageal cancer	1.19e-05	0.00055	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—MYC—esophageal cancer	1.19e-05	0.00055	CbGpPWpGaD
Raltitrexed—TYMS—Cell Cycle—TP53—esophageal cancer	9.73e-06	0.000452	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—CREBBP—esophageal cancer	8.58e-06	0.000398	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—NOS3—esophageal cancer	7.68e-06	0.000357	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—PTGS2—esophageal cancer	7.03e-06	0.000326	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—EP300—esophageal cancer	5.84e-06	0.000271	CbGpPWpGaD
Raltitrexed—TYMS—Metabolism—PIK3CA—esophageal cancer	4.32e-06	0.000201	CbGpPWpGaD
